Skip to navigation Skip to content

Cardiomyopathy (CM) Program in Pharmaceutical Benefits Scheme (PBS) 012-24041204

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and tafamidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Symptomatic obstructive HCM and listing dates

Symptomatic obstructive HCM is a genetic disease that thickens the walls of the heart, blocking or reducing the amount of blood taken in and pumped out to the body with each heartbeat.

Listing dates: mavacamten - 1 May 2024.

See Written Authority Required Drugs for more details.

ATTR-CM and listing dates

ATTR-CM is a protein disorder where abnormal and toxic proteins known as ‘amyloid fibrils’ build up in heart tissue and cause heart muscles to thicken and stiffen over time, eventually leading to heart failure.

Listing dates: tafamidis - 1 May 2024.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • item and restriction codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority approval requests

Written Authority Required Drugs